TWI298256B - Chloride channel opener - Google Patents

Chloride channel opener Download PDF

Info

Publication number
TWI298256B
TWI298256B TW091119830A TW91119830A TWI298256B TW I298256 B TWI298256 B TW I298256B TW 091119830 A TW091119830 A TW 091119830A TW 91119830 A TW91119830 A TW 91119830A TW I298256 B TWI298256 B TW I298256B
Authority
TW
Taiwan
Prior art keywords
group
compound
alkyl
carbon number
composition
Prior art date
Application number
TW091119830A
Other languages
English (en)
Chinese (zh)
Inventor
Ueno Ryuji
Cuppoletti John
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26980134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI298256(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of TWI298256B publication Critical patent/TWI298256B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW091119830A 2001-08-31 2002-08-30 Chloride channel opener TWI298256B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31591701P 2001-08-31 2001-08-31
US37210402P 2002-04-15 2002-04-15

Publications (1)

Publication Number Publication Date
TWI298256B true TWI298256B (en) 2008-07-01

Family

ID=26980134

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091119830A TWI298256B (en) 2001-08-31 2002-08-30 Chloride channel opener

Country Status (11)

Country Link
US (2) US7064148B2 (cg-RX-API-DMAC7.html)
EP (1) EP1420794B1 (cg-RX-API-DMAC7.html)
JP (2) JP4786866B2 (cg-RX-API-DMAC7.html)
AR (1) AR036391A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002330747B2 (cg-RX-API-DMAC7.html)
BR (1) BR0212233A (cg-RX-API-DMAC7.html)
CA (1) CA2458471C (cg-RX-API-DMAC7.html)
MX (1) MXPA04002006A (cg-RX-API-DMAC7.html)
NZ (1) NZ531503A (cg-RX-API-DMAC7.html)
TW (1) TWI298256B (cg-RX-API-DMAC7.html)
WO (1) WO2003030912A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1389116E (pt) * 2001-05-18 2008-04-11 Sucampo Ag Composição de indução catártica
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
PT1562604E (pt) * 2002-10-23 2012-04-09 Sucampo Ag Compostos de prostaglandina para o tratamento de obesidade
KR101164838B1 (ko) 2002-12-27 2012-07-11 수캄포 아게 복부 불쾌감 치료용 프로스타글랜딘의 유도체
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
ES2371658T3 (es) * 2005-04-12 2012-01-05 Sucampo Ag Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales.
US20070203228A1 (en) * 2006-02-28 2007-08-30 Sucampo Ag Method for treating chronic obstructive pulmonary disease
JP5427029B2 (ja) * 2006-09-06 2014-02-26 スキャンポ・アーゲー 消化管の重炭酸分泌を促進するための方法および組成物
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
AU2010280684B2 (en) * 2009-08-07 2016-07-28 Scipharm Sarl Composition for the treatment of cystic fibrosis
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
EA029760B1 (ru) * 2011-02-07 2018-05-31 Сифарм Сарл ПРИМЕНЕНИЕ КОМПОЗИЦИИ ПРОСТАЦИКЛИНА И ИНГИБИТОРА ФОСФОДИЭСТЕРАЗЫ 4 ИЛИ ИХ АНАЛОГОВ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА И УВЕЛИЧЕНИЯ цАМФ В ЭПИТЕЛИАЛЬНЫХ КЛЕТКАХ
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
US10724986B2 (en) 2012-11-29 2020-07-28 Indiana University Research & Technology Corporation Dielectric electrolyte measurement device
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
JP6090723B2 (ja) * 2013-10-04 2017-03-08 国立大学法人東北大学 腎機能障害の予防又は改善剤
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
WO2018074514A1 (ja) 2016-10-20 2018-04-26 ビオフェルミン製薬株式会社 腸管のイオン経細胞輸送体への作用剤、クロライドチャネル活性化剤、腎疾患の予防もしくは治療剤、又は排便促進剤
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE43462B1 (en) * 1975-06-23 1981-03-11 Pfizer Substituted tetranorprostaglandins
US4091207A (en) * 1976-04-22 1978-05-23 Pfizer Inc. Prostaglandin intermediate including oxathio heterocyclic ring
IT1098350B (it) * 1977-07-28 1985-09-07 Upjohn Co Derivati prostaglandinici
JPS6033429B2 (ja) * 1980-04-28 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
ATE78465T1 (de) * 1987-10-02 1992-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
JPH0791192B2 (ja) * 1989-11-22 1995-10-04 株式会社上野製薬応用研究所 ガス交換機能不全処置剤
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
TW249226B (cg-RX-API-DMAC7.html) 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6015828A (en) 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
CN100528166C (zh) * 1997-10-13 2009-08-19 苏坎波公司 门静脉高血压抑制剂
KR100648868B1 (ko) * 1997-11-28 2006-11-24 가부시키가이샤 아루떼꾸 우에노 엔도텔린 길항제
CN1144588C (zh) * 1998-05-25 2004-04-07 大正制药株式会社 睡眠诱发剂
KR100788226B1 (ko) 2000-03-24 2007-12-26 수캄포 아게 15-케토-프로스타글란딘 또는 이의 유도체를 포함하는세포자연사 억제 조성물
AU4472701A (en) 2000-04-06 2001-10-23 Sucampo Ag Bile secretion promoting composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
FR2829293B1 (fr) * 2001-08-31 2003-11-14 Centre Nat Rech Scient Memoire moleculaire et son procede de fabrication

Also Published As

Publication number Publication date
WO2003030912A1 (en) 2003-04-17
NZ531503A (en) 2006-01-27
CA2458471C (en) 2012-07-31
JP5568021B2 (ja) 2014-08-06
AU2002330747B2 (en) 2007-07-19
JP4786866B2 (ja) 2011-10-05
JP2011102313A (ja) 2011-05-26
US7064148B2 (en) 2006-06-20
CA2458471A1 (en) 2003-04-17
JP2005504836A (ja) 2005-02-17
AR036391A1 (es) 2004-09-08
US7253295B2 (en) 2007-08-07
EP1420794B1 (en) 2017-12-27
BR0212233A (pt) 2004-10-05
EP1420794A1 (en) 2004-05-26
MXPA04002006A (es) 2004-06-07
US20030130352A1 (en) 2003-07-10
US20060122411A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
TWI298256B (en) Chloride channel opener
AU2002330747A1 (en) Prostaglandin analogs as chloride channel opener
TWI225398B (en) Composition for treatment of external secretion disorders
TWI305147B (en) Cathartic composition
CN102014921A (zh) 用于调节干细胞生长的含前列腺素的组合物
TW209170B (cg-RX-API-DMAC7.html)
EP0366279A2 (en) Ocular hypotensive agents
TW200418491A (en) Pharmaceutical composition for treating abdominal discomfort
US8530519B2 (en) Method for promoting upper gastrointestinal bicarbonate secretion
US7459583B2 (en) Method for providing a cathartic effect
JP2002534389A (ja) 女性性機能障害の治療のための方法および組成物
TW205508B (cg-RX-API-DMAC7.html)
US20080207759A1 (en) Method for protecting mitochondria
JP2563158B2 (ja) ノナテトラエン酸誘導体
HK1252353A1 (zh) 治疗精神分裂症的方法
TW201102070A (en) Pharmaceutical composition for modulating claudin mediated functions
TWI281395B (en) Hydroxyeicosatetraenoic acid analogs, the composition thereof and use thereof in the manufacture of a medicament for treating dry eye and other disorders requiring the wetting of the eye in mammals
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
EP3008171A1 (en) Method for suppressing tumorigenicity of stem cells
US20120277299A1 (en) Method for modulating ion transporter
CA2870252A1 (en) Method for treating irritable bowel syndrome with diarrhea
US20060004107A1 (en) Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same
US20140212441A1 (en) Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent